RxDoctor Payments Data

Melvin Murphy, MD

Internal Medicine · Southfield, MINPI 1932288586

Payments from drug & device makers

$7,976in general payments, 2019–2025

Across 523 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Pfizer$1K
  • AstraZeneca$846
  • Bayer$806
  • GSK$474
  • Lilly USA, LLC$473
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$7,90199%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,976 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$56,617
Medicare patients
163
Services billed
920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide189$207,551
EliquisApixaban112$106,339
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$70,297
RybelsusSemaglutide46$56,944
JanuviaSitagliptin Phosphate40$41,127
JardianceEmpagliflozin53$40,858
MounjaroTirzepatide27$38,040
JanumetSitagliptin Phos/Metformin Hcl16$22,498
MyrbetriqMirabegron30$20,902
FarxigaDapagliflozin Propanediol13$19,178
EntrestoSacubitril/Valsartan20$15,091
XareltoRivaroxaban17$13,695
Saxagliptin-Metformin ErSaxagliptin Hcl/Metformin Hcl12$9,309
TradjentaLinagliptin17$8,928
Famotidine112$7,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,508$264,495235 claims
PfizerEliquis, Premarin$1,406$110,073131 claims
GSKTrelegy Ellipta$474$70,29794 claims
MerckJanuvia, Janumet$12$63,62556 claims
Boehringer IngelheimJardiance, Tradjenta$136$49,78670 claims
Lilly USA, LLCMounjaro$473$38,04027 claims
Astellas Pharma US IncMyrbetriq$346$20,90230 claims
AstraZenecaFarxiga$846$19,17813 claims
NovartisEntresto$380$15,09120 claims
Johnson & JohnsonXarelto$129$13,69517 claims
AbbVieSavella$67$5,39711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →